230 results on '"Jensen-Fangel S"'
Search Results
2. 308 An oral bicarbonate challenge test to measure CFTR function in cystic fibrosis
3. 357 Correction of the salt-losing phenotype in cystic fibrosis after elexacaftor-tezacaftor-ivacaftor treatment
4. P110 Change in sweat chloride concentration after elexacaftor/tezacaftor/ivacaftor initiation: results from 12 months follow-up in the Danish cystic fibrosis cohort
5. EPS6.03 Pulmonary pathogen prevalence 12 months after elexacaftor/tezacaftor/ivacaftor introduction: results from the Danish National Cystic Fibrosis Cohort
6. WS08.02 Change in hepatobiliary ultrasound measures, incl. shear wave elastography, after introduction of elexacaftor/tezacaftor/ivacaftor: results from 12-month follow-up in the Danish cystic fibrosis cohort
7. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
8. Intravenous antibiotics given for 2 weeks do not eradicate persistent Staphylococcus aureus clones in cystic fibrosis patients
9. 126 Change in pulmonary function after introduction of elexacaftor/tezacaftor/ivacaftor: Results from the national cystic fibrosis cohort in Denmark
10. 6 Decline in HbA1c during the first year on elexacaftor/tezacaftor/ivacaftor in the Danish cystic fibrosis population
11. 253 Change in liver biomarkers after introduction of elexacaftor/tezacaftor/ivacaftor: Results from a 12-month follow-up study in the national cystic fibrosis cohort in Denmark
12. 484 Change in pulmonary infections 12 months after elexacaftor/tezacaftor/ivacaftor introduction: Results from the Danish National Cystic Fibrosis Cohort
13. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis
14. Fatigue in Long Covid-19 is associated to short hospitalization time and normal lung function
15. P041 Clinical assessment plan for initiation and follow-up of treatment with elexacaftor/tezacaftor/ivacaftor in the Danish cystic fibrosis population
16. P145 Monitoring of pulmonary infections in the Danish cystic fibrosis cohort during CFTR modulator therapy implementation
17. WS06.06 The cystic fibrosis urine bicarbonate challenge test
18. Incidence of cervical dysplasia and cervical cancer in women living with HIV in Denmark: comparison with the general population
19. P150 Arthropathy in cystic fibrosis (protocol abstract)
20. P116 Elexacaftor/tezacaftor/ivacaftor during pregnancy: the effect on maternal ppFEV1
21. EPS3.02 The cystic fibrosis urine test: A comprehensive analysis of all renal acid-base parameters following acute oral bicarbonate loading
22. WS04.03 Elexacaftor/tezacaftor/ivacaftor (ETI) treatment corrects the salt-losing phenotype in people with cystic fibrosis (pwCF)
23. Phylogeny and Resistance profiles of HIV-1 POL Sequences From Rectal Biopsies and Blood
24. The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients
25. Ten Years of Extrapulmonary Tuberculosis in a Danish University Clinic
26. 129 Colistin resistance in Achromobacter sp. and Pseudomonas aeruginosa isolated from Danish cystic fibrosis patients is not related to plasmid-mediated expression of mcr-1
27. 346 Evaluation of home monitoring for patients with cystic fibrosis a feasibility study
28. 331 The nutritional status in cystic fibrosis patients with PEG tube and the long-term effects on BMI and pulmonary functions
29. EPS6.9 Validation of lung monitor for home monitoring of patients with cystic fibrosis. A feasibility study
30. Incidence of cervical dysplasia and cervical cancer in women living with HIV in Denmark:comparison with the general population
31. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.
32. Severe acute pancytopaenia in a patient with rheumatoid arthritis complicated by fatal invasive pulmonary aspergillosis
33. 63 Time to recurrence and antimicrobial susceptibility of first-time detected Achromobacter xylosoxidans in respiratory tract specimens from patients with cystic fibrosis
34. Incidence of cervical dysplasia and cervical cancer in women living with HIV in Denmark: comparison with the general population
35. 54 Limited transmission of non-tuberculous mycobacteria among Danish cystic fibrosis patients
36. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population
37. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study
38. Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenland HIV-infected population
39. 80 Therapeutical drug monitoring of piperacillin/tazobactam, given as continuous infusion to patients with cystic fibrosis
40. 221 Outpatient parenteral antimicrobial therapy (OPAT) in patients with cystic fibrosis
41. WS4.4 Multicenter prevalence study of nontuberculous mycobacteria in patients with cystic fibrosis in Scandinavia
42. Use of protease inhibitor saquinavir hard gel in human immunodeficiency virus-infected patients in the early period of highly active antiretrovital therapy::does it affect long-term treatment outcome
43. Ten years of extrapulmonary tuberculosis in a Danish university clinic
44. HIV i Vestdanmark
45. The Effect of Race/ethnicity on the outcome of Highly Active Antiretroviral Therapy in HIV-1 Infected Patients i West Denmark
46. Herpesvirus type 1-8 in BAL-fluids from HIV-1 infected patients with suspected pneumonia and in healthy individuals
47. Changing demographics in a HIV-infected population:Results from an observational cohort study in Western Denmark
48. Picture of the month: lymph node tuberculosis
49. Saquinavir hard gel supresses viral load insufficiently in hiv-infected patient naive to anti-retroviral therapy: a retrospective cohort study
50. Saquinavir hard gel suppresses viral load insufficiently in HIVinfected patients naive to antiretroviral therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.